In veterinary hospital pharmacies and contract manufacturing sites serving companion animal medicine, furaltadone hydrochloride is diluted with lactose monohydrate to produce hard gelatin capsules in 15 mg, 25 mg, and 50 mg strengths for bacterial enteritis and urinary tract infections caused by susceptible organisms. The direct-fill capsule route is selected when the API content remains below 20% w/w because the hydrochloride salt exhibits cohesive electrostatic behaviour above this concentration and because excipient dilution buffers the light-sensitive nitrofuran core during subsequent packaging. Formulation addition ratio follows the arithmetic of the fill weight: a 25 mg dose in a 250 mg fill body contains 10.0% w/w furaltadone hydrochloride, while a 50 mg dose in a 300 mg fill body contains 16.7% w/w. The blend is prepared by geometric dilution through a 425 µm stainless-steel sieve, then loaded into a 200 L V-blender operating at 20 rpm for 25 min; after the bulk blend meets content uniformity, magnesium stearate at 0.5% w/w and colloidal silicon dioxide at 0.2% w/w are added and mixed for an additional 5 min. Encapsulation is performed on a dosator-type capsule filler at 20 ± 2 °C and 30–35% RH, with fill weight tolerance maintained at ±4%; metal detection through a 2 mm aperture and final assay against Ph. Eur. 2.9.40 and USP <905> are used as release controls. Compliance for the capsule route is anchored to EU GMP Part II, ICH Q3D(R2), Ph. Eur. 2.9.3, and USP <711>, while the finished product is restricted to companion animals because EU Regulation 37/2010 Table 2 and FDA 21 CFR 530.41 prohibit nitrofuran use in food-producing species. The terminal finished dosage forms are veterinary hard gelatin capsules in 15 mg, 25 mg, and 50 mg strengths packaged in PVC/PE/PVDC blisters with light-protective aluminium foil.

Why Is Wet Granulation Preferred Over Direct Compression for Furaltadone HCl Tablets?

Direct compression is avoided when the furaltadone hydrochloride content in a tablet core approaches 20% w/w because the low bulk density and cohesive nature of the nitrofuran powder produce segregation and poor die-filling on high-speed rotary presses. Wet granulation with povidone K-30 at 3.0% w/w locks the active distribution into agglomerates with a final bulk density of approximately 0.50–0.60 g/mL and improves flowability measured by a repose angle below 35°. A 10 mg tablet core with a target mass of 120 mg contains 8.3% w/w API, crospovidone at 2.0% w/w, magnesium stearate at 0.5% w/w, and lactose monohydrate as filler; a 50 mg tablet core with a target mass of 250 mg contains 20.0% w/w API. Granulation is performed in a high-shear mixer with an impeller speed of 250 rpm and chopper at 1500 rpm; purified water is added at 12–18% w/w of the dry blend until a torque endpoint of 7–10 Nm is reached, after which the wet mass is passed through a 1.5 mm aperture and dried in a fluid-bed dryer at a product temperature of 55–60 °C until loss on drying is 2.0–3.5%. The dried granulate is blended with crospovidone and magnesium stearate, then compressed on a 16-station rotary tablet press with precompression at 4 kN and main compression between 8–12 kN; target tablet hardness is 60–90 N and friability is not more than 0.8%. Film-coating with a ready-to-use aqueous dispersion adds 3.0% weight gain in a side-vented pan at an inlet temperature of 65 °C and product temperature of 40 °C. In-process controls include Ph. Eur. 2.9.5 mass uniformity, Ph. Eur. 2.9.3 dissolution, and USP <905> content uniformity; residual moisture is maintained below 2.0% to reduce nitrofuran hydrolytic degradation. The terminal finished dosage forms are veterinary film-coated tablets in 10 mg, 20 mg, and 50 mg strengths packed in HDPE bottles with desiccant closures.

Oral granules destined for drinking-water administration in non-food-producing psittacine flocks and ornamental birds are manufactured by top-spray fluid-bed granulation so that the final agglomerates disperse within 120 seconds in potable water at 25 °C without leaving an oily or cohesive residue on water containers. The formulation uses 10.0% w/w furaltadone hydrochloride, 84.5% w/w lactose monohydrate, 3.0% w/w povidone K-30 as binder, 2.0% w/w anhydrous citric acid and sodium citrate dihydrate combined as a pH-modifying buffer, 0.3% w/w colloidal silicon dioxide, and 0.2% w/w sodium saccharin as a palatability adjunct. Fluid-bed processing is conducted in a top-spray granulator with inlet air at 65 °C, product bed temperature controlled at 30–34 °C, atomising air at 2.0 bar, and binder spray rate between 150–200 g/min per 50 kg batch; the granule fraction between 250 µm and 850 µm is retained for sachet filling, and final moisture is held below 2.0% to minimise nitrofuran degradation in humid storage. Release testing follows Ph. Eur. 2.9.5, Ph. Eur. 2.9.3, USP <621> for HPLC identity and assay, and ICH Q3D(R2) for elemental impurity control; marketing authorisation in the Union is governed by EU Regulation 2019/6, while EU Regulation 37/2010 Table 2 and FDA 21 CFR 530.41 provisions for nitrofuran residues in food animals do not confer an authorisation pathway for food-producing poultry and the product must be so labelled. The terminal finished dosage forms are 100 g and 500 g PET/ALU/LDPE sachets of drinking-water granules that are reconstituted in water immediately before administration.

When Injectable Solutions Are Sterile-Filtered Rather Than Autoclaved

Furaltadone hydrochloride injectable solutions are manufactured by aseptic filtration because the nitrofuran ring is sensitive to thermal hydrolysis under saturated steam terminal sterilisation, and published stability data for this specific configuration under 121 °C autoclave cycles are limited; therefore the conservative process selection avoids terminal heat treatment. The formulation is prepared at 10 mg/mL, equivalent to 1.0% w/v furaltadone hydrochloride, with sodium chloride at 8.5 mg/mL to achieve isotonicity and dilute hydrochloric acid or sodium hydroxide added to a final pH between 4.5 and 5.5. Compounding takes place in a Class C area with the sterile filtration and filling line in Grade A under EU GMP Annex 1 and ISO 14644-1 classifications; the solution is sparged with nitrogen to reduce oxidative degradation, passed through a 0.45 µm prefilter, then filtered through a 0.22 µm PVDF membrane with a pre-use water intrusion test and post-use bubble point test. Filling proceeds into 10 mL amber glass ampoules at 13,000–14,000 ampoules/h under laminar unidirectional airflow, followed by flame sealing to preserve sterility; no preservative is included in single-dose containers. Release tests include Ph. Eur. 2.6.1 sterility, Ph. Eur. 2.6.14 bacterial endotoxins, Ph. Eur. 2.9.19 sub-visible particulates, USP <71>, USP <85>, and USP <788>; assay and related substances are controlled by HPLC per USP <621>. The terminal finished dosage form is a sterile solution of furaltadone hydrochloride 10 mg/mL in 10 mL amber glass ampoules for parenteral administration to non-food-producing companion animals under veterinary prescription.

Roller-Compacted High-Dose Capsule Granules and the Segregation Threshold

Above 25% w/w furaltadone hydrochloride in a direct-fill capsule blend, the cohesive electrostatic properties of the unprocessed powder create segregation and poor dosator consistency; therefore roller compaction is used to densify the mixture before encapsulation. A 100 mg capsule with a 280 mg fill weight contains 35.7% w/w API, and the granulation is prepared by blending furaltadone hydrochloride with microcrystalline cellulose and lactose monohydrate before passing through a roll compactor with ribbed rolls at a specific compaction force of 8–12 kN/cm and a roll gap of 2 mm. The compacted ribbon is milled through a 0.8 mm screen at 50 rpm to yield granules between 200 µm and 700 µm, which increases bulk density from approximately 0.42 g/mL to 0.58 g/mL and improves capsule fill weight variability. Extragranular croscarmellose sodium at 2.0% w/w, magnesium stearate at 0.5% w/w, and colloidal silicon dioxide at 0.2% w/w are added after milling, followed by final blending in a bin blender for 15 min at 12 rpm. Process controls include USP <1174> powder flow, Ph. Eur. 2.9.36 flowability and bulk density, Ph. Eur. 2.9.40 content uniformity, and USP <905>; residual moisture is maintained below 2.0% and the granulate is protected from light throughout handling. The terminal finished dosage forms are hard gelatin capsules of 100 mg strength intended for large companion animals and non-food-producing species under veterinary prescription; packaging is light-protective aluminium/PVC blister or HDPE bottle with desiccant.